Crohn's disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• TNF 7
• IL-23 10
• JAK 0
• NLRP3 0
• IL-1 0
• GLP-1 0
• LRRK2 0
• IL-17 0
• IL-6 0
• MAPK 0
• PPAR 0
• CD19 3
• JNK 0
• STAT3 0
• TLR4 0
• TP53 0
• AKT 0
• AMPK 0
• BCMA 2
• CCR5 0
• IL-4 0
• NRF2 0
• SIRT1 0
• STING 0
• YAP 0
• ACE2 0
• AXL 0
• BRD4 0
• CD30 0
• CD40 0
• CD47 0
• COX-2 0
• CTLA-4 0
• DPP-4 0
• FTO 0
• G6PD 0
• GIP 0
• GPX4 0
• HDAC 1
• HIF-1 0
• HMGB1 0
• IL-13 0
• IL-15 1
• KMT2A 0
• MMP-9 0
• mTOR 0
• MUC1 0
• PARP 0
• PD-1 0
• PD-L1 0
• PDE4 0
• PI3K 0
• PINK1 0
• RAS 0
• RUNX1 0
• TFEB 0
• TYK2 0

4 of 4+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIDDK · R01

  Stem- and Paneth cell-specific CD74 functions control gut immune responses

  Rutgers Biomedical and Health Sciences· Newark, United States· US$780,495 awarded in fiscal year 2026· until Jun 2030

• NIH NIDDK · SB1

  Development of TP-317 for Ulcerative Colitis

  Thetis Pharmaceuticals, Llc· Deep River, United States· US$669,925 awarded in fiscal year 2026· until Jul 2028

• NIH NIDDK · R01

  Identification of bacterial derived proteases that inhibit inflammation and pain signaling in the gut

  Stanford University· Stanford, United States· US$3,802,100 awarded in fiscal year 2026· until Aug 2030

• NIH NIDDK · R44

  An allogeneic and gut specific Engineered T regulatory cell therapy for the treatment of Inflammatory Bowel Disease

  Gentibio, Inc.· Cambridge, United States· US$1,061,227 awarded in fiscal year 2026· until Aug 2028

• NIH NIDDK · R01

  Per- and poly-fluoroalkyl substances (PFAS) exposure and glycosylation alterations preceding inflammatory bowel disease

  Icahn School of Medicine at Mount Sinai· New York, United States· US$698,943 awarded in fiscal year 2026· until Jul 2031

• European Commission (Horizon Europe) · HORIZON-RIA

  Secretome bAsed Therapy for complex perianal fistUlas in CRohN’s disease (SATURN)

  Everzom· Paris, France· EU contribution €13,286,449· until Sept 2031· 5 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Characterising the molecular and cellular basis of enteric nervous system alterations in the inflamed gut (NeurogENSity)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €206,888· until Aug 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  A Fibroblast-Targeting Advanced Lead Mitigating Inflammation and Fibrosis in IBD (FIBROLEAD)

  Inolysis Monoprosopi Idiotiki Kefalaiouchiki Etaireia· Melissia Athens, Greece· EU contribution €150,000· until Jan 2027

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  RNA Epithelial Approach for Crohn’s Treatment (RE-ACT)

  Medical Research Infrastructure Development and Health Services Fund By the Sheba Medical Center· Ramat Gan, Israel· EU contribution €150,000· until Nov 2026

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Unravelling neuroimmune crosstalk to find novel treatment targets for inflammatory bowel disease (UNTANGLED)

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €432,468· until Apr 2028· 2 countries

10 of 295 running projects, newest first. Listed amounts together: US$145.7m + €63.7m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease

  NCT07250815· Takeda· Updated 15 Oct 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease

  NCT07250815· Takeda· Source

• Assessing the Drug Exposure Risk of Infants Breastfed by Women With Inflammatory Bowel Disease

  NCT03397108· The Hospital for Sick Children· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 22
• Organoids 13
• Mendelian Randomization Analysis 44
• Gene Expression Profiling 48
• Sequence Analysis, RNA 6
• Exome Sequencing 4
• Proteomics 14
• Metabolomics 23
• Mass Spectrometry 5
• Flow Cytometry 6
• Immunohistochemistry 9
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 76
• Machine Learning 36
• Deep Learning 13
• Cohort Studies 97
• Genome-Wide Association Study 58

• Targeting epithelial IFN-I signaling restores barrier integrity in anti-TNF refractory Crohn's disease.

  J Crohns Colitis, Sept 2026

• A scalable microarrayed organoid platform for precision modeling of intestinal epithelial damage and recovery.

  Cell Rep Methods, Aug 2026

• Epithelial CXCL1 tracks clinical remission in inflammatory bowel disease in a disease-specific manner.

  Front Immunol, Jul 2026

• BIRC3 (Encoding cIAP2) Variants Result in Dysregulated RIPK1 Signaling Leading to Increased Epithelial Cell Death and Are Associated With Monogenic Crohn's Disease.

  Gastroenterology, Jun 2026

• PPARγ controls I3C-mediated anti-inflammatory effects through the NF-κB/IL-6 pathway on gut inflammation models.

  Biomed Pharmacother, Jun 2026

• Culture-specific transcriptional drifts limit the fidelity of organoid infection models.

  PLoS Pathog, Jun 2026

• An inflammasome-driven differentiation program in intestinal stem cells protects against Salmonella infection.

  Nat Immunol, May 2026

• Organoid phenotypic screening identified glycyrrhizin that confers protection against tumor necrosis factor-induced cell death.

  Stem Cell Reports, Apr 2026

• Advancing drug discovery for inflammatory bowel diseases through human intestinal organoid-based models.

  Expert Opin Drug Discov, Apr 2026

• The emerging roles of intestinal organoid models in inflammatory bowel disease research.

  Expert Rev Gastroenterol Hepatol, Feb 2026

See which targets of this disease your abstract mentions, and go to the people working on them.